CORA-Q15: Continuous vs. Single-injection Interscalene Block on QoR-15 in Outpatient Rotator Cuff Surgery
Comparison of Continuous vs. Single-injection Interscalene Block on QoR-15 in Outpatient Rotator Cuff Surgery: A Randomized Study Assessing Non-inferiority and Superiority (CORA-Q15)
Pontificia Universidad Catolica de Chile
150 participants
May 26, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of the study will be to compare the efficacy of single-injection interscalene block versus continuous interscalene block on the quality of recovery in patients undergoing outpatient arthroscopic rotator cuff repair surgery. The participants will: * Be randomized to receive either a single-injection interscalene block or continuous infusion via an elastomeric pump. * Be monitored via telephone by the research team to complete the QoR-15 survey, assess pain levels, the need for tramadol use, and any complications. * Have follow-up by the Acute Pain Unit during the first 3 days.
Eligibility
Inclusion Criteria3
- Adults (≥18 years, \< 75 years) scheduled for elective outpatient arthroscopic rotator cuff repair surgery.
- Patients capable of managing a continuous outpatient regional analgesia system based on an interscalene block (eligibility criteria: able to understand verbal and written instructions, have home support, and live geographically close to the healthcare center).
- Willing and able to provide informed, written consent to participate in the study.
Exclusion Criteria4
- History of chronic opioid use (\>3 months).
- Severe comorbidities (e.g., renal or hepatic failure, ASA classification of 3 or higher).
- Allergy to local anesthetics, dexamethasone, or the analgesic drugs used in the study.
- Patients with contraindications for peripheral nerve block.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
infusion rate 4 ml/h, with 5 ml boluses (30-minute lockout). The PCA button disabled
infusion rate 0 ml/h, with 5 ml boluses (30-minute lockout). The PCA button will be enabled for rescue bolus administration
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06754657